Prostate Cancer Combo Extends Remission in High-Risk Patients

CHICAGO, IL – June 01, 2026 – A groundbreaking study has unveiled a powerful new combination therapy that significantly delays the progression of high-risk prostate cancer, offering more than a year of additional time before the disease worsens. The final results of the ZZ-FIRST trial, presented at the American Society of Clinical Oncology (ASCO) annual congress, show that adding the PARP inhibitor talazoparib to the standard hormonal treatment enzalutamide extended radiographic progression-free survival to 45.3 months, compared to 31.1 months for patients on enzalutamide alone.

This 14.2-month improvement represents a major leap forward for men diagnosed with high-volume metastatic hormone-sensitive prostate cancer (mHSPC), a particularly aggressive form of the disease with a historically poorer prognosis. The findings suggest a new strategy to proactively combat treatment resistance, one of the most significant challenges in modern oncology.

Tackling a Formidable Foe: The Challenge of Treatment Resistance

For men with prostate cancer that has spread, or metastasized, the primary goal of treatment is to block the male hormones, or androgens, that fuel the tumors. This is typically achieved with androgen deprivation therapy (ADT) combined with potent next-generation hormonal agents like enzalutamide. While initially effective for most, this strategy has a known vulnerability: over time, cancer cells can adapt, mutate, and learn to grow even in a low-androgen environment.

When this happens, the disease transitions to what is known as metastatic castration-resistant prostate cancer (mCRPC), a more aggressive and difficult-to-treat stage. Delaying this transition is a critical objective in prostate cancer care.

The ZZ-FIRST study tested an intensification strategy aimed at overwhelming the cancer from the outset. By pairing enzalutamide with talazoparib, a PARP inhibitor, the therapy delivers a two-pronged attack. While enzalutamide cuts off the hormonal fuel supply, talazoparib sabotages the cancer cells' internal repair mechanisms. PARP inhibitors block a key protein that cancer cells use to repair damage to their DNA. By inhibiting this repair process, the drug causes so much accumulated DNA damage that the cancer cells cannot survive, a concept known as synthetic lethality. This approach is particularly effective in tumors that already have weaknesses in their DNA repair pathways.

The ZZ-FIRST Study: A 14-Month Leap Forward

The ZZ-FIRST study, a phase II randomized trial managed by the international oncology research company MEDSIR, enrolled 54 patients with high-volume mHSPC across eight centers in Spain. These patients represent a high-risk population for whom improved upfront therapies are urgently needed. The primary goal was to measure radiographic progression-free survival, or the length of time patients lived without their cancer showing signs of growth on imaging scans.

The results presented at ASCO were definitive. Patients receiving the combination therapy not only gained over a year of progression-free survival but also showed a longer time until their PSA levels began to rise and a longer time until the cancer developed resistance to hormonal therapy. This indicates the combination doesn't just slow tumor growth but may fundamentally alter the timeline of the disease.

"Although patients with metastatic disease initially respond to hormonal therapy, the tumor eventually adapts and grows again," explained Dr. Joaquín Mateo, the study's principal investigator and an oncologist at Vall d'Hebron University Hospital. Presenting the data at ASCO, he added, "Therefore, it is essential to investigate the biological mechanisms that allow the tumor to develop resistance to hormonal treatment and to identify new therapeutic strategies capable of delaying or preventing this process."

The study also investigated tumor biology to understand how resistance develops, yielding key insights that could help identify which patients are most likely to benefit from this combination therapy in the future, particularly those with specific mutations in DNA repair genes.

Shifting the Paradigm in Advanced Prostate Cancer Care

The findings from ZZ-FIRST arrive at a time when the entire treatment paradigm for advanced prostate cancer is shifting. For years, the standard of care has been moving away from single-agent therapy toward early and aggressive treatment intensification. This study provides compelling evidence for a specific and highly effective combination.

While PARP inhibitors are already used in later stages of prostate cancer, particularly for patients with known DNA repair gene mutations like BRCA, the ZZ-FIRST results make a strong case for moving them much earlier in the treatment timeline for a broader group of high-risk patients. This proactive approach aims to prevent the emergence of resistance before it can even begin.

"These findings, if confirmed in larger trials, could fundamentally change our upfront approach for men with high-volume disease," commented a leading urologic oncologist not involved with the study. "Delaying castration resistance by over a year is not just statistically significant; it's clinically transformative for patients and their families, offering them more time with a better quality of life before needing to move to more toxic therapies."

The Collaborative Engine Behind the Breakthrough

This significant medical advance was made possible by a unique collaborative research model. The ZZ-FIRST study was orchestrated by MEDSIR, a company specializing in managing complex, investigator-driven clinical trials. The study's success highlights the power of a funding coalition that bridges multiple sectors.

External funding was provided by Pfizer S.L., the Spanish Association Against Cancer (AECC), and the United States Department of Defense (DoD). This diverse backing—uniting industry, a leading patient advocacy non-profit, and a major government research body—underscores the broad consensus on the importance of this research question. The drugs themselves were provided by Pfizer (talazoparib) and Astellas Pharma Europe Ltd. (enzalutamide), the two companies that jointly develop and market enzalutamide.

The success of ZZ-FIRST serves as a powerful blueprint for how to tackle the most complex challenges in cancer research, uniting different sectors toward the common goal of improving patient outcomes. The journey from a promising hypothesis to a practice-changing therapy is long, but studies like this demonstrate how innovative partnerships can significantly shorten the path.